(Q37973355)

26 August 2017

Adverse drug reactions to osteoporosis treatments (English)

1 reference

26 August 2017

0 references

2

Jean-Yves Reginster

1 reference

26 August 2017

1

René Rizzoli

1 reference

PubMed ID

22220306

26 August 2017

language of work or name

English

0 references

publication date

1 September 2011

1 reference

Expert Review of Clinical Pharmacology

26 August 2017

1 reference

26 August 2017

4

1 reference

26 August 2017

5

1 reference

26 August 2017

593-604

1 reference

Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients

26 August 2017

1 reference

Adverse reactions and drug-drug interactions in the management of women with postmenopausal osteoporosis

21 January 2018

1 reference

21 January 2018

1 reference

Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group

21 January 2018

1 reference

Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial

21 January 2018

1 reference

Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group

21 January 2018

1 reference

Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group.

21 January 2018

1 reference

Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group.

21 January 2018

1 reference

Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis.

21 January 2018

1 reference

Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis

21 January 2018

1 reference

Denosumab for prevention of fractures in postmenopausal women with osteoporosis

21 January 2018

1 reference

Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators

21 January 2018

1 reference

Skeletal effects of raloxifene after 8 years: results from the continuing outcomes relevant to Evista (CORE) study.

21 January 2018

1 reference

Lasofoxifene in postmenopausal women with osteoporosis

21 January 2018

1 reference

Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial

21 January 2018

1 reference

Bazedoxifene, a selective estrogen receptor modulator: effects on the endometrium, ovaries, and breast from a randomized controlled trial in osteoporotic postmenopausal women

21 January 2018

1 reference

The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis

21 January 2018

1 reference

Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study.

21 January 2018

1 reference

Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis

21 January 2018

1 reference

Osteoporosis treatments and adverse events

21 January 2018

1 reference

Safety considerations with bisphosphonates for the treatment of osteoporosis.

21 January 2018

1 reference

Safety of bisphosphonates in the treatment of osteoporosis

21 January 2018

1 reference

Long-term use of bisphosphonates in osteoporosis

21 January 2018

1 reference

Adverse effects of bisphosphonates

21 January 2018

1 reference

Bisphosphonates for post-menopausal osteoporosis: are they all the same?

21 January 2018

1 reference

Risks and benefits of bisphosphonates

21 January 2018

1 reference

Oral bisphosphonates and upper gastrointestinal tract problems: what is the evidence?

21 January 2018

1 reference

Oral bisphosphonates and risk of cancer of oesophagus, stomach, and colorectum: case-control analysis within a UK primary care cohort

21 January 2018

1 reference

Exposure to oral bisphosphonates and risk of esophageal cancer.

21 January 2018

1 reference

Bisphosphonates and esophageal cancer—a pathway through the confusion

21 January 2018

1 reference

Reports of esophageal cancer with oral bisphosphonate use.

21 January 2018

1 reference

Statins prevent bisphosphonate-induced gamma,delta-T-cell proliferation and activation in vitro.

21 January 2018

1 reference

Bisphosphonates and atrial fibrillation: Bayesian meta-analyses of randomized controlled trials and observational studies

21 January 2018

1 reference

Atrial fibrillation and bisphosphonate therapy

21 January 2018

1 reference

Alendronate and atrial fibrillation.

21 January 2018

1 reference

Use of alendronate and risk of incident atrial fibrillation in women

21 January 2018

1 reference

Use of bisphosphonates among women and risk of atrial fibrillation and flutter: population based case-control study

21 January 2018

1 reference

Low-energy femoral shaft fractures associated with alendronate use.

21 January 2018

1 reference

Unusual mid-shaft fractures during long-term bisphosphonate therapy

21 January 2018

1 reference

Low-energy femoral fractures associated with the long-term use of bisphosphonates: a case series from a Swiss university hospital

21 January 2018

1 reference

Subtrochanteric fractures after long-term treatment with bisphosphonates: a European Society on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, and International Osteoporosis Foundation Working Group Report

21 January 2018

1 reference

Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research

21 January 2018

1 reference

Association of low-energy femoral fractures with prolonged bisphosphonate use: a case control study

21 January 2018

1 reference

Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur.

21 January 2018

1 reference

Treatment of osteoporosis: recognizing and managing cutaneous adverse reactions and drug-induced hypersensitivity

21 January 2018

1 reference

Bisphosphonate-associated osteonecrosis: a long-term complication of bisphosphonate treatment

21 January 2018

1 reference

Osteonecrosis of the jaw and bisphosphonate treatment for osteoporosis

21 January 2018

1 reference

The epidemiology of osteonecrosis: findings from the GPRD and THIN databases in the UK

21 January 2018

1 reference

Bisphosphonate-associated osteonecrosis of the jaw: a key role of inflammation?

21 January 2018

1 reference

Renal safety of annual zoledronic acid infusions in osteoporotic postmenopausal women

21 January 2018

1 reference

Denosumab in men receiving androgen-deprivation therapy for prostate cancer

21 January 2018

1 reference

Efficacy and safety of denosumab in postmenopausal women with osteopenia or osteoporosis: a systematic review and a meta-analysis.

21 January 2018

1 reference

Do RANKL inhibitors (denosumab) affect inflammation and immunity?

21 January 2018

1 reference

Progesterone induces adult mammary stem cell expansion

21 January 2018

1 reference

Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer

21 January 2018

1 reference

Osteonecrosis of the jaws induced by anti-RANK ligand therapy

21 January 2018

1 reference

Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study

21 January 2018

1 reference

Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial

21 January 2018

1 reference

Design and methods of the Raloxifene Use for The Heart (RUTH) study

21 January 2018

1 reference

Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women

21 January 2018

1 reference

Characterization of hot flashes reported by healthy postmenopausal women receiving raloxifene or placebo during osteoporosis prevention trials

21 January 2018

1 reference

Safety assessment of raloxifene over eight years in a clinical trial setting

21 January 2018

1 reference

Raloxifene: a review of its use in postmenopausal osteoporosis

21 January 2018

1 reference

Safety and adverse effects associated with raloxifene: multiple outcomes of raloxifene evaluation

21 January 2018

1 reference

Vascular events in the Multiple Outcomes of Raloxifene Evaluation (MORE) trial: incidence, patient characteristics, and effect of raloxifene

21 January 2018

1 reference

Safety and tolerability of bazedoxifene in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled phase 3 trial

21 January 2018

1 reference

Effect of raloxifene on stroke and venous thromboembolism according to subgroups in postmenopausal women at increased risk of coronary heart disease

21 January 2018

1 reference

Effect of raloxifene on cardiovascular adverse events in postmenopausal women with osteoporosis

21 January 2018

1 reference

Effect of raloxifene on prevention of dementia and cognitive impairment in older women: the Multiple Outcomes of Raloxifene Evaluation (MORE) randomized trial

21 January 2018

1 reference

Prevention of osteoporosis and uterine effects in postmenopausal women taking raloxifene for 5 years

21 January 2018

1 reference

Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study

21 January 2018

1 reference

Osteoporosis and venous thromboembolism: a retrospective cohort study in the UK General Practice Research Database

21 January 2018

1 reference

Intelligent risk communication: can it be improved?

21 January 2018

1 reference

Teriparatide: a review of its use in osteoporosis.

21 January 2018

1 reference

Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebo-controlled trial

21 January 2018

1 reference

Bone neoplasms in F344 rats given teriparatide [rhPTH(1-34)] are dependent on duration of treatment and dose

21 January 2018

1 reference

Patients' understanding of risk associated with medication use: impact of European Commission guidelines and other risk scales

21 January 2018

1 reference

Inter-expert agreement of seven criteria in causality assessment of adverse drug reactions

21 January 2018

1 reference

Pharmacovigilance: methods, recent developments and future perspectives

21 January 2018

1 reference

Adverse drug reactions: definitions, diagnosis, and management

21 January 2018

1 reference

Osteoporosis: now and the future

21 January 2018

1 reference

Bisphosphonate-Associated Osteonecrosis of the Jaw: Report of a Task Force of the American Society for Bone and Mineral Research

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1586/ECP.11.42

1 reference

26 August 2017

1 reference

PubMed ID

22220306